Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 2083-2085, 2003; 10.1373/clinchem.2003.023747
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, B. Y.Y.
Right arrow Articles by Fraser, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, B. Y.Y.
Right arrow Articles by Fraser, W. D.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:2083-2085.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Effect of Anticoagulants and Storage Temperature on the Stability of Receptor Activator for Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in Plasma and Serum

Benjamin Y.Y. Chan1, Katherine A. Buckley2, Brian H. Durham1, James A. Gallagher2 and William D. Fraser1,a

1 Department of Clinical Chemistry, Royal Liverpool University Hospital, The University of Liverpool, and2 Human Bone Cell Research Group, Department of Human Anatomy and Cell Biology, The University of Liverpool, Liverpool, L69 3GA, UK

aaddress correspondence to this author at: Department of Clinical Chemistry, 4th Floor Duncan Bldg., Liverpool L69 3GA, UK; fax 44-151-706-5813, e-mail w.d.fraser@liverpool.ac.uk

The first 300 words of the full text of this article appear below.

The discovery of receptor activator for nuclear factor-{kappa}B ligand (RANKL) and osteoprotegerin (OPG) as the fundamental factors controlling osteoclast formation and activation has advanced the understanding of the processes involved in osteoclastogenesis and bone remodeling (1)(2)(3). RANKL is important for osteoclast survival, differentiation, maturation, and activation, whereas OPG opposes these actions. Expression of RANKL and OPG is altered in many bone remodeling disorders, suggesting that determination of the role of these proteins in bone diseases is of value in understanding their etiology (4).

Accurate quantification of sRANKL and OPG concentrations in serum samples is paramount in research involving metabolic bone disease. The availability of ELISAs for both sRANKL and OPG has led to investigation of the concentrations of these proteins in human samples collected from patients with several disorders and has allowed monitoring of the effect of treatment in bone-related diseases (4)(5)(6)(7)(8)(9). Previous reports of OPG concentrations in postmenopausal women with osteoporosis have produced discordant results in relation to bone turnover (5)(8). Other reports using the sRANKL:OPG ratio to estimate the extent of Paget disease of bone and the effect of bisphosphonate treatment have also shown inconclusive and inconsistent results (9)(10)(11). These data suggest a possible variability in sRANKL and OPG measurements in human serum or plasma. In this study we aimed to clarify whether this variability is attributable to genuine differences among the groups of patients studied or whether it reflects inaccuracies resulting from the sampling process. We investigated several factors that may influence the concentrations of sRANKL and OPG in human blood samples by (a) collecting blood into different anticoagulants; (b) varying the time between blood collection . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Nybo, S. P. Johnsen, C. Dethlefsen, K. Overvad, A. Tjonneland, J. O. L. Jorgensen, and L. M. Rasmussen
Lack of Observed Association between High Plasma Osteoprotegerin Concentrations and Ischemic Stroke Risk in a Healthy Population
Clin. Chem., December 1, 2008; 54(12): 1969 - 1974.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Nybo and L. M Rasmussen
The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review
Eur. J. Endocrinol., November 1, 2008; 159(5): 603 - 608.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Joseph, B. Y. Chan, B. H. Durham, A. M. Ahmad, S. Vinjamuri, J. A. Gallagher, J. P. Vora, and W. D. Fraser
The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3230 - 3238.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Stern, G. A Laughlin, J. Bergstrom, and E. Barrett-Connor
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor {kappa}B legend with bone mineral density in older adults: the Rancho Bernardo Study
Eur. J. Endocrinol., May 1, 2007; 156(5): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.